Sugi Predict

Sugi Predict / Compounds / 4-Benzyloxyaniline

4-Benzyloxyaniline

4-Benzyloxyaniline

SCHEMBL7097006

CS(=O)(=O)Nc1ccc(OCc2ccccc2)cc1.Nc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 12/20 0.86
▸ RAB9A P51151 3/20 0.86
▸ SMN1; SMN2 Q16637 3/20 0.86
▸ NPC1 O15118 2/20 0.86
▸ HPGD P15428 1/20 0.86
▸ GAA P10253 1/20 0.64
▸ MAPT P10636 1/20 0.64
▸ MAOA P21397 1/20 0.64
▸ MAOB P27338 1/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ PGR P06401 2/20 0.55
▸ CA12 O43570 2/20 0.52
▸ CA1 P00915 2/20 0.52
▸ CA2 P00918 2/20 0.52
▸ CA9 Q16790 2/20 0.52
▸ CA4 P22748 1/20 0.52
▸ CA5A P35218 1/20 0.52
▸ CA7 P43166 1/20 0.52
▸ CA5B Q9Y2D0 1/20 0.52
▸ LTA4H P09960 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7096964 0.93 AR (1.00) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL9387480 0.80 KEAP1 (0.76) ARRAB9ASMN1; SMN2NPC1HPGD
4-Benzyloxyaniline SCHEMBL171449 0.80 MAOB (1.00) RAB9ASMN1; SMN2NPC1GAAMAPT
4-Benzyloxyaniline SCHEMBL371743 0.78 MAOB (0.96) RAB9ASMN1; SMN2NPC1GAAMAPT
4-Benzyloxyaniline SCHEMBL5376217 0.78 MAOB (0.96) RAB9ASMN1; SMN2NPC1GAAMAPT
SCHEMBL7262553 0.78 AR (0.72) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL7094939 0.77 AR (0.71) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL27183288 0.77 AR (0.70) ARRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL656210 0.76 CA1 (0.63) SMN1; SMN2HPGDMAPTPGRCA12
Benzylphenylether SCHEMBL8999674 0.76 AR (0.69) ARRAB9ASMN1; SMN2NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605618-B2 Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction WYETH 2003-08-12 — — US disclosed
US-20030018045-A1 Heterocyclic beta-3 adrenergic receptor agonists WYETH (US) 2003-01-23 — — US disclosed
US-6451814-B1 SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION WYETH 2002-09-17 — — US disclosed
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018045-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB2, ADRB1, ADRB3 AR 471/4885RAB9A 1800/4885SMN1; SMN2 3162/4885
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 AR 438/4885RAB9A 1702/4885SMN1; SMN2 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.